Saturday 17 October 2026
Export ADXN’s income statement to Excel — free account
Addex Therapeutics Ltd. Sponsored ADR
ADXN Healthcare Biotechnology
In the quarter to June 2026, revenue fell 100.8%, EPS grew 25.7% and free cash flow fell 2.73%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
2.76
0.26
−8.61%
Follow ADXN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | 68.53 | 38.74 | |
P/FCF ratio |
— | — | 0.00 | 0.00 | |
P/Operating CF |
— | — | (10.13) | (12.61) | |
P/B ratio |
— | — | 1.20 | 1.19 | |
Price to Tangible BV |
— | — | 1.21 | 1.20 | |
EV/Sales |
— | — | 48.91 | 26.82 | |
EV/EBITDA |
— | — | 0.00 | 0.00 | |
EV/Operating CF |
— | — | (1.88) | (3.31) | |
EV/FCF |
— | — | (1.88) | (3.30) | |
Quick Ratio |
0.58 | 0.79 | 1.38 | 1.91 | |
Current Ratio |
0.76 | 0.97 | 1.40 | 2.01 | |
Net Debt/EBITDA |
1.24 | 1.99 | 2.06 | 3.15 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.01 | 0.02 | |
Operating CF/Net income |
0.26 | 0.45 | 0.30 | 0.36 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(544.40) | (180.09) | 90.99 | (869.90) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | (6,760.00%) | 769.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | (92,050.00%) | 1,742.86% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | (1,150.00%) | 55.26% | |
Graham Net Nets |
— | — | 0.01 | 0.14 | |
Graham Number |
— | — | 0.00 | 0.00 | |
Earnings Yield |
— | — | (120.76%) | (85.58%) | |
Free Cash Flow Yield |
— | — | (37.99%) | (20.99%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.04 | |
Operating CF per Share |
(0.57) | (0.99) | (0.76) | (0.75) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.57) | (0.99) | (0.76) | (0.75) | |
Cash per Share |
0.95 | 1.21 | 2.21 | 2.91 | |
Shareholders Equity per Share |
2.36 | 4.25 | 6.43 | 7.93 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.36 | 4.25 | 6.43 | 7.93 | |
Free Cash Flow |
(0.58) | (0.98) | (0.68) | (0.70) | |
Working Capital |
(0.41) | (0.04) | 0.58 | 1.49 | |
Net Current Asset Value |
(0.68) | (0.36) | 0.10 | 1.24 | |
EV/EBIT |
— | — | 0.00 | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
Price to Operating Income |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.04 | 0.04 | 0.02 | 0.31 | |
Average Payables |
1.49 | 1.23 | 1.17 | 1.24 | |
Average Assets |
7.36 | 8.31 | 9.91 | 11.61 | |
Average Common Equity |
5.58 | 6.71 | 8.37 | 10.11 |
Columns are period end dates · fundamentals updated 30 Sep 2026